{"@id":"https://bioecon.ru/technology/viro-immunotherapeutics/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://cn.bioecon.ru/technology/viro-immunotherapeutics/","json":"https://cn.bioecon.ru/api/v1/technology/viro-immunotherapeutics/index.json"},"id":"viro-immunotherapeutics","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/genscript-probio-genscript/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/spiber-technologies-ab/","https://bioecon.ru/companies/loopworm/"]},"maturity":7,"name":"工程化溶瘤病毒免疫治疗与广谱抗感染疫苗平台","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"病毒毒力基因减毒与肿瘤特异性复制锁定"},{"n":2,"title":"免疫激活多因子嵌合武装改造"},{"n":3,"title":"影像引导瘤内高精度注射或静脉隐蔽递送"},{"n":4,"title":"原位恶性细胞坏死性凋亡与远端免疫响应"}],"summary":"通过分子工程改造的肿瘤选择性重组溶瘤病毒系统（HSV、VSV或腺病毒），敲除必需毒力基因限制其仅在p53/Rb缺失的恶性细胞中爆发复制，并装载GM-CSF、IL-12或BiTE分子，引发剧烈原位溶解与全身抗原激活。","url":"/technology/viro-immunotherapeutics/","verified":"2026-11-22"}